MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets

Overview

Journal Curr Drug Targets

Publisher Bentham Science Publishers

Specialty Pharmacology

Date 2010 Apr 8

PMID 20370647

Citations 4

Authors

Yousaf A Mian

Nancy J Zeleznik-Le

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNA) are small non-coding RNAs of approximately 22 nucleotides that regulate the translation and stability of mRNA to control different functions of the cell. Misexpression of miRNA has been linked to disruption of normal cellular functions, which results in various disorders including cancers such as leukemias. MicroRNA involvement in disease has been the subject of much attention and is increasing our current understanding of disease biology. Such linkages have been determined by high-throughput studies, which provide a framework for characterizing differential miRNA expression levels correlating to different cytogenetic abnormalities and their corresponding malignancies. In addition, functional studies of particular miRNAs have begun to define the effects of miRNA on predicted mRNA targets. It is clear that miRNAs can serve as molecular markers of leukemias and the hope is that they can also serve as new therapeutic targets. Studies are beginning to elucidate how to deliver therapeutic antagonists to attenuate overexpressed miRNAs and to replace underexpressed miRNAs. In this review, we: i) discuss the current understanding of miRNA function and expression in normal hematopoiesis, ii) provide examples of miRNAs that are misregulated in leukemias, and iii) evaluate the current status and potential future directions for the burgeoning field of antisense oligonucleotides and other therapeutic attempts to intervene in miRNA disregulation in leukemias.

Citing Articles

The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.

Mian Y, Zeleznik-Le N Leuk Res. 2016; 46:51-60.

PMID: 27123834 PMC: 4899285. DOI: 10.1016/j.leukres.2016.04.006.

Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.

Mulero-Navarro S, Sevilla A, Roman A, Lee D, DSouza S, Pardo S Cell Rep. 2015; 13(3):504-515.

PMID: 26456833 PMC: 4618050. DOI: 10.1016/j.celrep.2015.09.019.

Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.

Jinlong S, Lin F, Yonghui L, Li Y, Weidong W PLoS One. 2015; 10(2):e0118099.

PMID: 25646775 PMC: 4315415. DOI: 10.1371/journal.pone.0118099.

Aberrant microRNA expression and its implications in the pathogenesis of leukemias.

Babashah S, Sadeghizadeh M, Rezaei Tavirani M, Farivar S, Soleimani M Cell Oncol (Dordr). 2012; 35(5):317-34.

PMID: 22956261 DOI: 10.1007/s13402-012-0095-3.

References

Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I . Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007; 35(22):e149. PMC: 2190705. DOI: 10.1093/nar/gkm971. View

Nagel S, Venturini L, Przybylski G, Grabarczyk P, Schmidt C, Meyer C . Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2009; 50(1):101-8. DOI: 10.1080/10428190802626632. View

Whitehead K, Langer R, Anderson D . Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8(2):129-38. PMC: 7097568. DOI: 10.1038/nrd2742. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Chen C, Li L, Lodish H, Bartel D . MicroRNAs modulate hematopoietic lineage differentiation. Science. 2003; 303(5654):83-6. DOI: 10.1126/science.1091903. View

Ebert M, Neilson J, Sharp P . MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007; 4(9):721-6. PMC: 3857099. DOI: 10.1038/nmeth1079. View

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis M, Nervi C . A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell. 2005; 123(5):819-31. DOI: 10.1016/j.cell.2005.09.023. View

Agirre X, Jimenez-Velasco A, Jose-Eneriz E, Garate L, Bandres E, Cordeu L . Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008; 6(12):1830-40. DOI: 10.1158/1541-7786.MCR-08-0167. View

10.

Ramkissoon S, Mainwaring L, Ogasawara Y, Keyvanfar K, McCoy Jr J, Sloand E . Hematopoietic-specific microRNA expression in human cells. Leuk Res. 2005; 30(5):643-7. DOI: 10.1016/j.leukres.2005.09.001. View

11.

Bichi R, Shinton S, Martin E, Koval A, Calin G, Cesari R . Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002; 99(10):6955-60. PMC: 124510. DOI: 10.1073/pnas.102181599. View

12.

Denli A, Tops B, Plasterk R, Ketting R, Hannon G . Processing of primary microRNAs by the Microprocessor complex. Nature. 2004; 432(7014):231-5. DOI: 10.1038/nature03049. View

13.

Alexis F, Pridgen E, Molnar L, Farokhzad O . Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008; 5(4):505-15. PMC: 2663893. DOI: 10.1021/mp800051m. View

14.

Reinhart B, Slack F, Basson M, Pasquinelli A, Bettinger J, Rougvie A . The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000; 403(6772):901-6. DOI: 10.1038/35002607. View

15.

Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M . The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Nat Cell Biol. 2006; 8(3):278-84. DOI: 10.1038/ncb1373. View

16.

Raty J, Pikkarainen J, Wirth T, Yla-Herttuala S . Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol. 2009; 1(1):13-23. DOI: 10.2174/1874467210801010013. View

17.

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

18.

Popovic R, Zeleznik-Le N . MLL: how complex does it get?. J Cell Biochem. 2005; 95(2):234-42. DOI: 10.1002/jcb.20430. View

19.

Braasch D, Corey D . Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol. 2001; 8(1):1-7. DOI: 10.1016/s1074-5521(00)00058-2. View

20.

Lee I, Ajay S, In Yook J, Kim H, Hong S, Kim N . New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. Genome Res. 2009; 19(7):1175-83. PMC: 2704433. DOI: 10.1101/gr.089367.108. View